145 related articles for article (PubMed ID: 38008193)
1. High content screening strategies for large-scale compound libraries with a focus on high-containment viruses.
Subramani C; Sharma G; Chaira T; Barman TK
Antiviral Res; 2024 Jan; 221():105764. PubMed ID: 38008193
[TBL] [Abstract][Full Text] [Related]
2. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
3. Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay.
Elshabrawy HA; Fan J; Haddad CS; Ratia K; Broder CC; Caffrey M; Prabhakar BS
J Virol; 2014 Apr; 88(8):4353-65. PubMed ID: 24501399
[TBL] [Abstract][Full Text] [Related]
4. Screening methods for influenza antiviral drug discovery.
Atkins C; Evans CW; White EL; Noah JW
Expert Opin Drug Discov; 2012 May; 7(5):429-38. PubMed ID: 22435452
[TBL] [Abstract][Full Text] [Related]
5. A comparative high-throughput screening protocol to identify entry inhibitors of enveloped viruses.
Wang J; Cheng H; Ratia K; Varhegyi E; Hendrickson WG; Li J; Rong L
J Biomol Screen; 2014 Jan; 19(1):100-7. PubMed ID: 23821643
[TBL] [Abstract][Full Text] [Related]
6. Biological activity-based modeling identifies antiviral leads against SARS-CoV-2.
Huang R; Xu M; Zhu H; Chen CZ; Zhu W; Lee EM; He S; Zhang L; Zhao J; Shamim K; Bougie D; Huang W; Xia M; Hall MD; Lo D; Simeonov A; Austin CP; Qiu X; Tang H; Zheng W
Nat Biotechnol; 2021 Jun; 39(6):747-753. PubMed ID: 33623157
[TBL] [Abstract][Full Text] [Related]
7. Development of a robust and convenient dual-reporter high-throughput screening assay for SARS-CoV-2 antiviral drug discovery.
Chiu W; Schepers J; Francken T; Vangeel L; Abbasi K; Jochmans D; De Jonghe S; Thibaut HJ; Thiel V; Neyts J; Laporte M; Leyssen P
Antiviral Res; 2023 Feb; 210():105506. PubMed ID: 36565756
[TBL] [Abstract][Full Text] [Related]
8. High-content image-based screening of a signal transduction pathway inhibitor small-molecule library against highly pathogenic RNA viruses.
Mudhasani R; Kota KP; Retterer C; Tran JP; Tritsch SR; Zamani R; Whitehouse CA; Bavari S
J Biomol Screen; 2015 Jan; 20(1):141-52. PubMed ID: 25342145
[TBL] [Abstract][Full Text] [Related]
9. A fluorescence-based high throughput-screening assay for the SARS-CoV RNA synthesis complex.
Eydoux C; Fattorini V; Shannon A; Le TT; Didier B; Canard B; Guillemot JC
J Virol Methods; 2021 Feb; 288():114013. PubMed ID: 33166547
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective.
Seifert M; Bera SC; van Nies P; Kirchdoerfer RN; Shannon A; Le TT; Meng X; Xia H; Wood JM; Harris LD; Papini FS; Arnold JJ; Almo S; Grove TL; Shi PY; Xiang Y; Canard B; Depken M; Cameron CE; Dulin D
Elife; 2021 Oct; 10():. PubMed ID: 34617885
[TBL] [Abstract][Full Text] [Related]
11. Antiviral drug discovery: preparing for the next pandemic.
Adamson CS; Chibale K; Goss RJM; Jaspars M; Newman DJ; Dorrington RA
Chem Soc Rev; 2021 Mar; 50(6):3647-3655. PubMed ID: 33524090
[TBL] [Abstract][Full Text] [Related]
12. Cell-Based High-Throughput Screening Protocol for Discovering Antiviral Inhibitors Against SARS-COV-2 Main Protease (3CLpro).
Rothan HA; Teoh TC
Mol Biotechnol; 2021 Mar; 63(3):240-248. PubMed ID: 33464543
[TBL] [Abstract][Full Text] [Related]
13. A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry.
Xu M; Pradhan M; Gorshkov K; Petersen JD; Shen M; Guo H; Zhu W; Klumpp-Thomas C; Michael S; Itkin M; Itkin Z; Straus MR; Zimmerberg J; Zheng W; Whittaker GR; Chen CZ
SLAS Discov; 2022 Mar; 27(2):86-94. PubMed ID: 35086793
[TBL] [Abstract][Full Text] [Related]
14. Review on
Cetin Y; Aydinlik S; Gungor A; Kan T; Avsar T; Durdagi S
Curr Med Chem; 2022; 29(38):5925-5948. PubMed ID: 35761502
[TBL] [Abstract][Full Text] [Related]
15. High-throughput screening of viral entry inhibitors using pseudotyped virus.
Basu A; Mills DM; Bowlin TL
Curr Protoc Pharmacol; 2010 Dec; Chapter 13():Unit 13B.3. PubMed ID: 21935898
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 replicon for high-throughput antiviral screening.
Zhang QY; Deng CL; Liu J; Li JQ; Zhang HQ; Li N; Zhang YN; Li XD; Zhang B; Xu Y; Ye HQ
J Gen Virol; 2021 May; 102(5):. PubMed ID: 33956592
[TBL] [Abstract][Full Text] [Related]
17. Concise review: a high-content screening approach to stem cell research and drug discovery.
Xia X; Wong ST
Stem Cells; 2012 Sep; 30(9):1800-7. PubMed ID: 22821636
[TBL] [Abstract][Full Text] [Related]
18. A high-throughput drug screening strategy against coronaviruses.
Liu J; Li K; Cheng L; Shao J; Yang S; Zhang W; Zhou G; de Vries AAF; Yu Z
Int J Infect Dis; 2021 Feb; 103():300-304. PubMed ID: 33333250
[TBL] [Abstract][Full Text] [Related]
19. Reporter Replicons for Antiviral Drug Discovery against Positive Single-Stranded RNA Viruses.
Fernandes RS; Freire MCLC; Bueno RV; Godoy AS; Gil LHVG; Oliva G
Viruses; 2020 May; 12(6):. PubMed ID: 32486283
[TBL] [Abstract][Full Text] [Related]
20. iPSC screening for drug repurposing identifies anti-RNA virus agents modulating host cell susceptibility.
Imamura K; Sakurai Y; Enami T; Shibukawa R; Nishi Y; Ohta A; Shu T; Kawaguchi J; Okada S; Hoenen T; Yasuda J; Inoue H
FEBS Open Bio; 2021 May; 11(5):1452-1464. PubMed ID: 33822489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
